Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF FINANCIAL OFFICER | January 26, 2026 | January 29, 2026 |
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | CFO and Treasurer | January 22, 2021 | January 26, 2021 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date January 26, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,521 |
Reported balance
After 2026-01-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-26 · Sale · Disposed 3,746 · Balance 24,521 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.
INTERCEPT PHARMACEUTICALS, INC.
Report date January 22, 2021 · Filed January 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,964 |
Reported balance
After 2021-01-22 transaction · row 1
1 source rowRow 1 · 2021-01-22 · Grant · Acquired 17,200 · Balance 40,964 F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2031-01-22 | Direct | 26,900 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Grant · Acquired 26,900 · Balance 26,900 F2: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021.
F2: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2021 Filed May 28, 2021 22:01 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,918 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001209191-21-036625 · doc4.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Underlying: Common Stock · 16,918 shares Expires 2031-05-26 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 20:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 230,000 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0000899243-21-014161 · doc4.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2031-03-29 F2 · derivative.exercise_date: The stock option vests with respect to 50% of the underlying shares on March 29, 2023, and will vest with respect to the remainder of the shares in 24 equal monthly installments thereafter. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 20:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014161 · doc4.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of restricted stock units, which will vest with respect to 50% of the underlying shares on March 29, 2023, and in two equal annual installments thereafter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F1 · derivative.exercise_date: Represents an award of restricted stock units, which will vest with respect to 50% of the underlying shares on March 29, 2023, and in two equal annual installments thereafter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F1 · derivative.expiration_date: Represents an award of restricted stock units, which will vest with respect to 50% of the underlying shares on March 29, 2023, and in two equal annual installments thereafter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 26,900 | $0.00 Strike: $29.46 | $0.00 |
DisclosureSEC source: 0001104659-21-007782 · tm214232-5_4seq1.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 26,900 shares Expires 2031-01-22 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 17,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-007782 · tm214232-5_4seq1.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,964 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021. Read SEC document |
| January 05, 2021 Filed Jan 5, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 2,193 | $24.47 | $53,662.71 |
DisclosureSEC source: 0001104659-21-001123 · tm211606-5_4seq1.xml · nonDerivative · entry 3 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,764 F3 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 342 | $24.70 | $8,447.40 |
DisclosureSEC source: 0001104659-21-001123 · tm211606-5_4seq1.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,957 F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 859 | $24.70 | $21,217.30 |
DisclosureSEC source: 0001104659-21-001123 · tm211606-5_4seq1.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,299 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,763 | $32.78 | $57,791.14 |
DisclosureSEC source: 0001104659-20-136448 · tm2038708d1_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,158 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 296 | $42.08 | $12,455.68 |
DisclosureSEC source: 0001104659-20-112317 · tm2032461d2_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,921 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 615 | $46.52 | $28,609.80 |
DisclosureSEC source: 0001104659-20-081438 · tm2024073d5_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,217 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 615 | $58.40 | $35,916.00 |
DisclosureSEC source: 0001104659-20-043287 · tm2014981d5_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,832 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 23:43 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 5,000 | $18.00 | $90,000.00 |
DisclosureSEC source: 0001209191-20-015628 · doc4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:56 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,918 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014698 · doc4.xml · derivative · entry 1 Kapadia Sandip · CIK 0001677141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Underlying: Common Stock · 16,918 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 9,200 | $0.00 Strike: $99.66 | $0.00 |
DisclosureSEC source: 0001104659-20-007266 · tm205922d7_4.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2030-01-23 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-007266 · tm205922d7_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,447 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 669 | $123.92 | $82,902.48 |
DisclosureSEC source: 0001104659-20-001091 · tm201209d8_4.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,847 F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 551 | $123.92 | $68,279.92 |
DisclosureSEC source: 0001104659-20-001091 · tm201209d8_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,516 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 626 | $65.87 | $41,234.62 |
DisclosureSEC source: 0001144204-19-047218 · tv530559_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,067 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 615 | $79.17 | $48,689.55 |
DisclosureSEC source: 0001144204-19-033816 · tv524735_form4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,693 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 615 | $111.50 | $68,572.50 |
DisclosureSEC source: 0001144204-19-018079 · tv517925_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,308 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock and restricted stock unit awards previously granted to the reporting person. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 7,200 | $0.00 Strike: $110.80 | $0.00 |
DisclosureSEC source: 0001144204-19-002140 · tv511181_4.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Stock · 7,200 shares Expires 2029-01-16 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2019. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-002140 · tv511181_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,923 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2019. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,118 | $100.79 | $112,683.22 |
DisclosureSEC source: 0001144204-19-000499 · tv510190_form4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,423 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock and restricted stock units. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 531 | $126.46 | $67,150.26 |
DisclosureSEC source: 0001144204-18-052406 · tv503774_4.xml · nonDerivative · entry 4 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| July 01, 2018 Filed Oct 3, 2018 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 468 | $83.91 | $39,269.88 |
DisclosureSEC source: 0001144204-18-052406 · tv503774_4.xml · nonDerivative · entry 3 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| April 01, 2018 Filed Oct 3, 2018 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 468 | $61.52 | $28,791.36 |
DisclosureSEC source: 0001144204-18-052406 · tv503774_4.xml · nonDerivative · entry 2 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| February 05, 2018 Filed Feb 22, 2018 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 10,500 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001144204-18-010357 · tv486820_4.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2028-02-05 F2 · derivative.exercise_date: 25% of the shares of common stock underlying this option will vest on January 1, 2019, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2022 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| February 05, 2018 Filed Feb 22, 2018 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-010357 · tv486820_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,115 F1 · shares: Represents shares of common stock underlying restricted stock units ("RSUs") granted on February 5, 2018, with each RSU representing the contingent right to receive one share of common stock upon vesting of the RSU. 25% of the shares of common stock underlying these RSUs will vest on January 1, 2019, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares of common stock underlying the RSUs will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2022 (representing the vesting on each such vesting date of 6.25% of the shares of common stock initially underlying these RSUs), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| January 01, 2018 Filed Oct 3, 2018 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,107 | $58.42 | $64,670.94 |
DisclosureSEC source: 0001144204-18-052406 · tv503774_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 354 | $58.83 | $20,826.74 |
DisclosureSEC source: 0001144204-17-051416 · v476463_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,215 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,431 | $121.59 | $173,999.15 |
DisclosureSEC source: 0001144204-17-035813 · v470324_form4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,569 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 11,600 | $0.00 Strike: $107.18 | $0.00 |
DisclosureSEC source: 0001144204-17-006033 · v458367_4.xml · derivative · entry 2 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires 2027-07-01 F2 · derivative.exercise_date: 25% of the shares of common stock underlying this option will vest on July 1, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through July 1, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006033 · v458367_4.xml · nonDerivative · entry 1 Kapadia Sandip · CIK 0001677141 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · shares: 25% of the shares of restricted stock will vest on July 1, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through July 1, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.